SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Gorilla and King Portfolio Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Uncle Frank who wrote (12349)12/8/1999 2:44:00 AM
From: johnzhang  Read Replies (1) of 54805
 
RE: VISX Competition

Uncle Frank,

I presume competitors would still have to get fda approval for their systems, even if the visx patents aren't upheld. From what I've seen that represents a significant barrier to entry in terms of time to market.

Yes, FDA approval is required for newly developed medical device and instrument to be sold in US, and it's typically a lengthy process. However, several Visx's competitors have either system that is already approved by FDA or system that is currently undergoing clinical trials. Before the ruling, competitors have to pay Visx loyalties for their products. If the ruling is upheld, some of these loyalty payments would likely stop. Therefore, Visx shareholders should watch closely the outcome of its fight against the ruling.

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News